ravive, Inc. (NASDAQ:ARAV, ", the Company", ))))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies.
Related Posts
Nvidia Expands Global Reach, Collaborates With Singtel for AI-Driven Data Centers in Southeast Asia
Singtel partners with Nvidia to offer AI capabilities in Southeast Asian data centers, addressing growing demand for Nvidia chips and expanding into new markets.
Morgan Stanley Maintains Overweight on IBM, Lowers Price Target to $155
Morgan Stanley analyst Erik Woodring maintains IBM (NYSE:IBM) with a Overweight and lowers the price target from $157 to $155.
JinkoSolar Signed MoU With Failte Solar To Supply 200MW Of N Type Tiger Neo Modules For Irish Distribution Generation Market
JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE:JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that it has signed a Memorandum of Understanding